TTrialPathMatch Me to Trials
← Back to trials
RecruitingObstructive Sleep Apnea

Pharmacological Activation of HMN for OSA Aim 2

Eligible age

18–70 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201AZ, LTM1201AT, LTM1201AD, LTM1201AG administered before sleep on OSA phenotype traits and OSA severity during sleep.

Sponsor: Brigham and Women's Hospital

You may qualify if…

  • ✓ AHI \> 10 events/h during NREM supine sleep

You may not qualify if…

  • ✕ Any medical condition other than well controlled hypertension and mild diabetes.
  • ✕ Any medication known to influence breathing, sleep/arousal, or muscle physiology.
  • ✕ Claustrophobia.
  • ✕ Inability to sleep supine.
  • ✕ Allergy to any of the medications tested in the protocol.
  • ✕ History of kidney stones, hypercalcemia, primary hyperparathyroidism, sarcoidosis, hypervitaminosis D.
  • ✕ Individuals with underlying cardiac disease, such as arrhythmias.
  • ✕ Individuals taking psychiatric medications, such as an MAO-I, SSRI or SNRI, or any of the studied medications for medical care.

Where it's recruiting

Massachusetts

Boston

Source: ClinicalTrials.gov · NCT03858751 · last updated 2022-09-21

Pharmacological Activation of HMN for OSA Aim 2 · TrialPath